A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Condition studied

Metastatic Microsatellite Stable Colorectal Cancer

Investigational medicinal product(s)

Every trial of INCA33890, Calcium folinate, Fluorouracil and Oxaliplatin across our registers →

Eligibility

Primary endpoint

PFS, defined as the time from the date of randomization to the date of the first documented progression as determined by BICR (Blinded Independent Central Review) per RECIST v1.1 or death due to any cause.

Endpoint detail

OS, defined as the time from the date of randomization to the date of death due to any cause., Objective response, defined as CR or PR as determined by BICR (Blinded Independent Central Review) per RECIST v1.1., DOR, defined as the time from the earliest date of documented response until the earliest date of disease progression as determined by BICR per RECIST v1.1 or death due to any cause, whichever occurs first., TEAEs per CTCAE v6.0 and TEAEs leading to dose interruption or study drug discontinuation.